Pharmaceutical Utilization Strategies for Serious Infections
Medium: Webcast On-Demand
Release Date: Monday, November 22, 2010
Credit Expiration Date: Tuesday, November 22, 2011
Physician CME: 1.25
Physician Assistants Hours: 1.25
Pharmacists CPE: 1.25
"Pharmaceutical Utilization Strategies for Serious Infections" is a Webcast
On-Demand based on an independent CME/CE symposium held on October 14, 2010
in St. Louis, Missouri. This Webcast On-Demand consists of 2 Learning
Modules that discuss the burden of serious infections and their appropriate
management and prevention strategies.
Hospital-acquired Infections (HAIs) Module
Invasive Fungal Infections (IFIs) Module
- The Burden of HAIs – George G. Zhanel, PharmD, PhD
- Improving Quality Control Through Preventive Measures: Reducing the Risk of HAIs – Marin H. Kollef, MD
- Promoting Antimicrobial Stewardship for Serious Bacterial Infections – James S. Lewis, PharmD
Note: If you have received credit by attending the live symposium by the same name, you
are not eligible to apply for credit for this online version.
- The Burden of HAIs – George G. Zhanel, PharmD, PhD
- Assessing the Value of New Diagnostic Approaches in Clinical Mycology: A Potential Win-Win Situation – Marin H. Kollef, MD
- Antifungal Prophylaxis in High-Risk Patients: Managing Costs Through Prevention – Richard H. Drew, PharmD, MS
Practice Gap and Educational Need
Serious bacterial and fungal infections can place a heavy burden on healthcare
systems that are currently struggling to reduce costs while maintaining patient
quality of care. In addition to the increased morbidity and mortality associated
with these infections, the economic costs can be insurmountable, mainly
attributable to prolonged length of stay in hospitals and ICUs. Inappropriate
treatment, often caused by pathogen resistance, further increases hospital
resource utilization while having a detrimental impact on patient outcomes.
To address the challenges of serious bacterial and fungal infections in hospitalized
patients, evidence-based strategies have been developed. Preventive tactics, including
infection control and prophylaxis, have proven to be effective in reducing the
incidence of hospital-acquired infections. The latest diagnostic techniques allow
for early detection of infection that can guide appropriate initial treatment.
Finally, antimicrobial stewardship efforts have aimed to decrease the inappropriate
use of antibiotics and minimize the risk for resistance development.
Effectively utilizing these tactics will require a multiprofessional team
approach, of which managed care pharmacists can play a leading role.
This activity is designed to meet the needs of healthcare professionals who are
on the frontline of preventing and appropriately managing serious infections
in the hospital and managed care environment and, thus, responsible for
promoting patient safety.
Healthcare professionals participating in this educational activity will, at its conclusion, be better able to:
- Define evidence-based tactics to reduce the risk of serious hospital infections
- Apply antimicrobial stewardship principles to improve patient quality of care
- Analyze the latest approaches to prevent and treat invasive fungal infections
Richard H. Drew, PharmD, MS, BCPS
Professor, Campbell University School of Pharmacy
Associate Professor of Medicine, Infectious Diseases
Duke University School of Medicine
Marin H. Kollef, MD, FACP, FCCP
Golman Professor of Medicine, Division of Pulmonary and Critical Care Medicine
Director, Medical Intensive Care Unit
Director, Respiratory Care Services
St. Louis, MO
James S. Lewis, PharmD
Infectious Diseases Pharmacy Programs Manager
University Health System Department of Pharmacy
Clinical Assistant Professor
University of Texas Health Sciences Center
San Antonio, TX
George G. Zhanel, PharmD, PhD
Professor, Department of Medical Microbiology and Infectious Diseases
Faculty of Medicine, University of Manitoba
Accreditation Statement: This activity has been planned and implemented in accordance with
the Essential Areas and Policies of the Accreditation Council for Continuing Medical
Education (ACCME) through joint sponsorship of Center for Independent Healthcare
Education (Center) and Vemco MedEd. Center is accredited by the ACCME to provide continuing
medical education for physicians.
Credit Designation: Center designates for this activity a maximum of 1.25 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Academy of Physician Assistants accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME. Physician assistants
may receive a maximum of 1.25 hours of Category I credit for completing this activity.
Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for
Pharmacy Education as a provider of continuing pharmacy education. Center has assigned 1.25 contact
hours (0.125 CEUs) for this activity.
ACPE Universal Activity Number: 0473-9999-10-008-H01-P
Type of Activity: Knowledge-based
Method of Participation and Instruction for Credit
Documentation of credit will be mailed within 4 weeks of receipt of the completed
Post Test, Evaluation, and Credit Application form.
- Review the entire CME/CE information including target
audience, learning objectives, and disclosures.
- Review both Learning Modules.
- Complete the Post Test, Evaluation, and Credit Application form.
- Mail the completed Post Test, Evaluation, and Credit Application
form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 Or Fax to (908) 450-3300.
Disclosure of Conflicts of Interest
Center for Independent Healthcare Education requires faculty, planners, and others who are in a position to
control the content of continuing education activities to disclose to the audience any real or apparent
conflict of interest related to the activity. All identified conflicts of interest are reviewed to ensure
fair balance, objectivity, and scientific rigor in all activities. The faculty is further required to
disclose discussion of off-label uses in their presentations.
Richard H. Drew, PharmD
Consultant: Astellas, Ortho-McNeil, Wyeth/Pfizer, and Merck/Schering-Plough
Development team: CustomID
Research support: Merck/Schering-Plough and Cubist
Speaker honorarium: Merck/Schering-Plough, Ortho-McNeil, Moses Cone Health System, Society of
Critical Care Medicine, and American Society of Microbiology
Publication royalties: UpToDate
Marin H. Kollef, MD
Advisory board: Theravance
Speaker bureau: Pfizer, Merck, and Astellas
James S. Lewis, PharmD
Advisory boards and consultant: Pfizer, Astellas, Merck, and Ortho-McNeil
Speaker bureau: Astellas
George G. Zhanel, PhD, PharmD
Research/grant support: Abbott, Astellas, Affinium, Merck, Pfizer, Bayer, and Ortho-McNeil
Speaker bureau: Merck, Pfizer, Ortho-McNeil, and Abbott
Disclosure: Planning Committee
Employees of Center for Independent Healthcare Education and Vemco MedEd have no
relevant financial relationships to disclose.
Disclosure of Off-label Use
The following off-label uses of antimicrobial/antifungal agents and other products
are discussed during this activity: oritavancin, iclaprim, ceftobiprole, and ceftaroline
for the treatment of MRSA infections; doripenem for the treatment of ventilator-associated
pneumonia (VAP); Lactobacillus for the prevention of VAP; fluconazole for prophylaxis in
liver transplant patients; itraconazole, liposomal amphotericin B, caspofungin, and
voriconazole for the prevention of invasive fungal infections.
This activity is jointly sponsored by Center for Independent Healthcare Education and Vemco MedEd.
This activity is supported by an educational grant from Astellas Pharma US, Inc.
There is no fee to participate in this activity.
Microsoft Internet Explorer or Mozilla Firefox
Note: Please disable any “pop-up blocker” features.
Adobe® Flash® Player to view the presentations (If you do not have Adobe® Flash® Player, you can
download it for free from get.adobe.com/flashplayer)
Adobe Acrobat Reader version 4 or above to view PDF files (If you do not have Acrobat Reader, you can download it
for free from get.adobe.com/reader)
Cable, DSL, or better of at least 300 kbps
PC or Macintosh to view the presentations
Please e-mail any questions or concerns to email@example.com.
Copyright © 2010 Vemco MedEd, LLC. All Rights Reserved.
Permission for accreditation use granted to Center for Independent Healthcare Education.
The opinions expressed in this educational activity are those of the faculty and do not reflect the views of
Center for Independent Healthcare Education (Center) and Vemco MedEd. This educational activity may discuss
off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been
approved by the United States Food and Drug Administration (FDA). Center and Vemco MedEd do not recommend the
use of any product/procedure outside of the labeled indications. A qualified healthcare professional should be
consulted before using any therapeutic product/procedure discussed. Clinicians should verify all information and
data before treating patients or employing any therapies described in this continuing education activity. Please
refer to the prescribing information for each product/procedure for approved
indication, contraindications, and warnings.
For questions regarding the accreditation of this activity, please contact Center for Independent Healthcare
Education at firstname.lastname@example.org
By clicking on the following icons, I acknowledge that I have read the
entire CME/CE information.